详情页 - 首都医科大学附属北京同仁医院知识库

当前位置：首页 > 详情页

Fungal Plasma Membrane H+-ATPase: Structure, Mechanism, and Drug Discovery

9| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China. [2]Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing 100005, China. [3]Department of Biophysics, School of Basic Medical Sciences, Peking University, Beijing 100083, China.

出处：

DOI：

ISSN：

关键词： fungi plasma membrane H+-ATPase structure drug target

摘要：

The fungal plasma membrane H+-ATPase (Pma1) pumps protons out of the cell to maintain the transmembrane electrochemical gradient and membrane potential. As an essential P-type ATPase uniquely found in fungi and plants, Pma1 is an attractive antifungal drug target. Two recent Cryo-EM studies on Pma1 have revealed its hexameric architecture, autoinhibitory and activation mechanisms, and proton transport mechanism. These structures provide new perspectives for the development of antifungal drugs targeting Pma1. In this article, we review the history of Pma1 structure determination, the latest structural insights into Pma1, and drug discoveries targeting Pma1.

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 2 区生物学

小类 | 2 区真菌学 3 区微生物学

最新[2023]版：

大类 | 2 区生物学

小类 | 2 区真菌学 3 区微生物学

JCR分区：

出版当年[2022]版：

Q2 MICROBIOLOGY Q2 MYCOLOGY

最新[2023]版：

Q1 MYCOLOGY Q2 MICROBIOLOGY

影响因子： 4.2 最新[2023版] 4.5 最新五年平均 4.7 出版当年[2022版] 5.2 出版当年五年平均 5.724 出版前一年[2021版] 4.2 出版后一年[2023版]

第一作者：

第一作者机构： [1]Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China. [2]Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing 100005, China.

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Structure and activation mechanism of the hexameric plasma membrane H+-ATPase [2]Pim-1 kinase as cancer drug target: An update. [3]Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles [4]Correction: Identification of kukoamine a as an anti-osteoporosis drug target using network pharmacology and experiment verification [5]A meta-analysis for CXCRCR4 as a prognostic marker and potential drug target in non-small cell lung cancer [6]Identification of kukoamine a as an anti-osteoporosis drug target using network pharmacology and experiment verification [7]Biomimetic and multifunctional nanocomposites for precision fungi theranostics [8]Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development [9]Keratitis-Associated Fungi Form Biofilms with Reduced Antifungal Drug Susceptibility [10]Chemoproteomics and Phosphoproteomics Profiling Reveals Salvianolic Acid A as a Covalent Inhibitor of mTORC1